Roberto Guerciolini is now chief medical officer of Skyhawk Therapeutics. Guerciolini’s experience includes posts at Wave Life Sciences (NASDAQ: [[ticker:WVE]]), SIRNA Therapeutics, and Dicerna Pharmaceuticals (NASDAQ: [[ticker:DRNA]]). Waltham, MA-based Skyhawk is developing RNA-targeting drugs to treat cancer and neurological diseases. Skyhawk launched a little more than a year ago; last June, the company landed a partnership with Celgene (NASDAQ: [[ticker:CELG]]) and simultaneously announced a $40 million round of funding.